Should I Buy Teva Pharmaceuticals (TEVA)? Finance YouTuber Analysis

The YouTuber recommends Teva Pharmaceuticals, highlighting its strong cash flow, debt reduction, and undervaluation despite weak sales growth. He anticipates future growth from its biosimilars venture with Alvotech, expecting FDA approvals soon, and sets a price target of $12, seeing it as a relatively safe investment.

“Teva is strongly cash flow positive paying down debt and is very undervalued. We can look at some of the valuation statistics of this company .67 times on a price to sales just 1.88 Enterprise Revenue to Enterprise Value to revenue if you compare that to Other Drug makers you see how cheap this stock really is on a target of $12 a share.”

Teva is extremely undervalued, trading at 1.85x Enterprise Value to Revenue, significantly below its historical average and peers like Bristol Myers Squibb (3x EV/R). The company has put its M&A debt and opioid crisis behind it, and a return to average valuation multiples could see the stock price double or triple.

“Teva trading for about 1.85 Times Enterprise Value to revenue that is even even in the worst circumstances should not be that low should be at least three or four times even if it were to match Bristol Meer squib three times Enterprise Value to revenue if we got three divided by where it's trading at right now 1.85 that is a 62% higher 62% return 8.44 that is $1 1360 per share $13.68 per share where TAA could could be trading for even if it just came up to that three times Enterprise Value to revenue uh two Revenue multiple that Bristol Meers squib is trading for”

Teva Pharmaceuticals is considered a favorite value play, having resolved opioid litigation and actively paying down debt. Despite expectations of flat sales growth, its valuation at 3.7 times earnings is deemed unbelievably cheap, with a fair value estimated between $10 and $12.

“Teva Pharmaceuticals took our Teva it's going to be reporting its earnings on Tuesday as well and it remains one of my favorite value plays here”

The analyst views Teva Pharmaceuticals as deeply undervalued, trading at just 3 times P/E, which is half of its peers. The company recently settled its nationwide opioid lawsuit, clearing a major hurdle, and is aggressively paying down its significant debt while generating $1 billion in free cash flow annually. He sees substantial upside potential.

“Tifa Pharmaceuticals ticker Teva this is another big position in my portfolio been talking about this over about the last year they announced a closure of its Nationwide opioid settlement last week a move that really clears a major hurdle for these shares.”

The YouTuber owns Teva shares and sees strong upside, with a target price of at least $12. The company has significantly improved its financial health by paying off over $12 billion in debt and settling opioid litigation. It trades at a low P/E of 3.7 times this year's expected earnings, with earnings projected to grow 5% next year.

“The company is expected to report two dollars and forty cents in earnings per share this year and trades for a price of just 3.7 times that that's earnings expected five percent higher next year as shares recently fell on a denial now for its biological application by the FDA but the upside remains strong here I do own the shares I own about 15 000 shares here Target price of at least twelve dollars over the next year.”

The YouTuber is adding to his position in Teva Pharmaceuticals after an 11% drop due to an FDA application denial. He believes the application will eventually be approved and highlights the stock's low valuation at 3.4 times 2023 expected earnings, an 85% discount to the pharma industry average. He notes the company's successful turnaround plan, including debt reduction and opioid litigation settlements, generating billions in free cash flow.

“I'm adding to my position on last week's drop and have a Target price of 12 a share over the next year.”

The YouTuber sees Teva as a deep value stock with significant upside catalysts. The company, the world's largest generic drug maker, has been paying down its substantial debt and is nearing resolution of opioid litigation. Its valuation is significantly discounted compared to peers on both price-to-sales and enterprise value-to-sales metrics, suggesting a potential share price of $15-$17.50.

“My perspective here in this one is not not necessarily a growth stock like the last one but a deep value stock with significant catalysts to the upside.”

The YouTuber suggests Teva Pharmaceuticals as a strong value stock, highlighting its position as the world's largest generic drug maker and a robust pipeline of branded medications. Despite past issues with debt from acquisitions and ongoing opioid litigation, recent positive legal news has stabilized the stock. It trades at a low valuation of four times earnings and 0.63 times sales, significantly below its historical price-to-sales ratio.

“shares of tiva shot up ten percent on that news but are still in the value territory trading for just four times on a price-to-earnings basis and just 0.63 times sales”